NHD Global
Cosmetic & Skin · Source-reviewed dossier
Source-Reviewed Research Dossier
Melanotan II is a cyclic α-MSH analogue acting at multiple melanocortin receptors. It is not an FDA-approved tanning medicine, and published reports include serious adverse events after unregulated use.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A published case described systemic toxicity with rhabdomyolysis after Melanotan II use.
A case report cannot estimate incidence but identifies a credible serious-harm signal.
Read the primary studyA clinical report documented prolonged priapism and systemic effects after Melanotan II overdose.
Unregulated product composition and dose add uncertainty rather than reassurance.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
A case report cannot estimate incidence but identifies a credible serious-harm signal.
View primary recordUnregulated product composition and dose add uncertainty rather than reassurance.
View primary recordThird-party publications selected for direct relevance.
Case report. 2012. PMID 23121206.
Case report. 2013. PMID 23537392.
Concise answers for researchers comparing identity, evidence and catalog variants.
Melanotan II is a cyclic α-MSH analogue acting at multiple melanocortin receptors. It is not an FDA-approved tanning medicine, and published reports include serious adverse events after unregulated use.
The human literature includes small experiments and case reports, with no approved product and meaningful safety uncertainty.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Melanotan II has limited early human exposure data and documented harms from unregulated use. A three-person tanning pilot cannot outweigh later toxicity reports or…
Updated September 8, 2026
Melanotan II is a cyclic heptapeptide analogue of α-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.
Updated September 8, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: MT2 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
